Certolizumab pegol in the treatment of psoriasis: Real-life data.
COVID-19
anti-TNF
certolizumab pegol
chronic plaque psoriasis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
03
01
2021
received:
14
10
2020
accepted:
27
02
2021
pubmed:
6
3
2021
medline:
10
6
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
Certolizumab pegol (CZP), the only Fc-free, PEGylated anti-tumor necrosis factor biologic agent. This study aims to investigate the effect and safety of CZP in moderate-to-severe chronic plaque psoriasis. We performed a retrospective observational analysis of the moderate-to-severe psoriasis patients under ceratolizumab pegol therapy. Primer endpoints were efficacy of CZP, defined as statistically significant improvement of Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA), and clinical Disease Activity index for Psoriatic Arthritis (cDAPSA) in the 24 week of therapy. Secondary endpoints were safety of CZP especially during COVID-19 pandemic. Fifty-six moderate-to-severe psoriasis patients treated with CZP were evaluated retrospectively. We observed a rapid and significant reduction of PASI, PGA, and cDAPSA scores in W4. After loading dose, we observed loss of clinical efficacy of CZP in eight patients and optimized therapy by increasing the dosing of CZP. Dose escalation of CZP permitted the achievement and long-term maintenance of clinical improvement in these patients. We compare the clinical efficacy of CZP between naive and patients who has been treated with other biologic agents. There were no statistical differences in efficacy between these two groups. No side effects were observed during CZP treatment. There were no cases of death from COVID-related disease in our study population or patients hospitalized for COVID-19 related disease. Our results demonstrate that CZP is an effective and safe therapeutic option for patients with moderate-to-severe chronic plaque psoriasis.
Substances chimiques
Antirheumatic Agents
0
Certolizumab Pegol
UMD07X179E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14929Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol. 2003;17:257-270.
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-873.
Dattola A, Cannizzaro MV, Mazzeo M, Bianchi L. Certolizumab pegol in the treatment of psoriasis and psoriatic arthritis: preliminary real-life data. Dermatol Ther. 2017;7:485-492.
Carubbi F. Safety and efficacy of certolizumab pegol in a reallife cohort of patients with psoriasis and psoriatic arthritis. J Dermatolog Treat. 2020;31:692-697.
Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79:302-314.
Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79:266-276.
Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167:658-667.
Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.
Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228-233.
Conforti C, Giuffrida R, Dianzani C, et al. COVID-19 and psoriasis: is it time to limit treatment with immunosup pressants? A call for action. Dermatol Ther. 2020;33:13298.
Megna M, Ruggiero A, Marasca C, et al. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31:1-2.
Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:16-25.